JP2023532293A5 - - Google Patents

Info

Publication number
JP2023532293A5
JP2023532293A5 JP2022580312A JP2022580312A JP2023532293A5 JP 2023532293 A5 JP2023532293 A5 JP 2023532293A5 JP 2022580312 A JP2022580312 A JP 2022580312A JP 2022580312 A JP2022580312 A JP 2022580312A JP 2023532293 A5 JP2023532293 A5 JP 2023532293A5
Authority
JP
Japan
Prior art keywords
nme7
sequence
cancer
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580312A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532293A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/036500 external-priority patent/WO2021252551A2/en
Application filed filed Critical
Priority claimed from PCT/US2021/039291 external-priority patent/WO2021263227A2/en
Publication of JP2023532293A publication Critical patent/JP2023532293A/ja
Publication of JP2023532293A5 publication Critical patent/JP2023532293A5/ja
Pending legal-status Critical Current

Links

JP2022580312A 2020-06-26 2021-06-27 抗ｎｍｅ抗体および癌または癌転移の治療方法 Pending JP2023532293A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063044670P 2020-06-26 2020-06-26
US63/044,670 2020-06-26
US202063046852P 2020-07-01 2020-07-01
US63/046,852 2020-07-01
PCT/US2021/036500 WO2021252551A2 (en) 2020-06-08 2021-06-08 Anti-nme antibody and method of treating cancer or cancer metastasis
USPCT/US2021/036500 2021-06-08
PCT/US2021/039291 WO2021263227A2 (en) 2020-06-26 2021-06-27 Anti-nme antibody and method of treating cancer or cancer metastasis

Publications (2)

Publication Number Publication Date
JP2023532293A JP2023532293A (ja) 2023-07-27
JP2023532293A5 true JP2023532293A5 (cg-RX-API-DMAC7.html) 2024-06-28

Family

ID=79281989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580312A Pending JP2023532293A (ja) 2020-06-26 2021-06-27 抗ｎｍｅ抗体および癌または癌転移の治療方法

Country Status (9)

Country Link
US (2) US20230242678A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172215A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023532293A (cg-RX-API-DMAC7.html)
KR (1) KR20230028796A (cg-RX-API-DMAC7.html)
CN (1) CN116075318A (cg-RX-API-DMAC7.html)
AU (1) AU2021297535A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183682A1 (cg-RX-API-DMAC7.html)
IL (1) IL299332A (cg-RX-API-DMAC7.html)
WO (1) WO2021263227A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015243948B2 (en) 2014-04-07 2020-10-15 Minerva Biotechnologies Corporation Anti-NME antibody
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
EP4161970A4 (en) 2020-06-08 2024-07-10 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5874285A (en) 1996-09-13 1999-02-23 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a novel human nm23-like protein
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
AU3347900A (en) 1999-01-23 2000-08-07 Minerva Biotechnologies Corporation Interaction of colloid-immobilized species with species on non-colloidal structures
AU3474100A (en) 1999-01-25 2000-08-07 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
WO2002001230A2 (en) 2000-06-23 2002-01-03 Minerva Biotechnologies Corporation Rapid and sensitive detection of protein aggregation
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
AU2001265403A1 (en) 2000-05-26 2001-12-11 Minerva Biotechnologies Corporation Metallocenes as signal-transducer for detection of chemical or biological events
WO2002001228A2 (en) 2000-06-23 2002-01-03 Minerva Biotechnologies Corporation Interaction of colloid-immobilized species with species on non-colloidal structures
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
JP4585170B2 (ja) 2000-10-03 2010-11-24 ミナーヴァ・バイオテクノロジーズ・コーポレーション 流動の中断に基づく相互作用の電子検出および相互作用の検出
AU2002219971A1 (en) 2000-11-01 2002-05-15 Minerva Biotechnologies Corporation Detection of binding species with colloidal and non-colloidal structures
JP4516273B2 (ja) 2000-11-15 2010-08-04 ミナーヴァ・バイオテクノロジーズ・コーポレーション オリゴヌクレオチド識別子
EP2241887B1 (en) 2000-11-27 2015-01-14 Minerva Biotechnologies Corporation Diagnostics, drug screening and treatment for cancer
WO2003018846A1 (en) 2001-08-31 2003-03-06 Minerva Biotechnologies Corporation Affinity tag modified particles
WO2003020280A2 (en) 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and use thereof in the treatment of cancer
EP2329822A1 (en) 2001-09-05 2011-06-08 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
US20050163784A1 (en) 2002-06-17 2005-07-28 Valentijn Linda J. Novel cancer therapies
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
CA2537263C (en) 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
AU2003299643A1 (en) 2002-12-04 2004-06-23 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
JP2006517674A (ja) 2002-12-20 2006-07-27 ミネルバ バイオテクノロジーズ コーポレーション ナノ粒子を含む光学デバイスおよび方法
CA2584412C (en) 2004-09-14 2017-05-09 Minerva Biotechnologies Corporation Methods for diagnosis and treatment of cancer
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
ES2720288T3 (es) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferación de células que expresan MUC1
ES2624863T3 (es) 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
WO2007072221A2 (en) 2005-11-10 2007-06-28 Aurelium Biopharma Inc. Surface marker-directed cancer therapeutics
US20090075926A1 (en) 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
US20100254996A1 (en) 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
US20090092603A1 (en) 2007-09-25 2009-04-09 Bamdad Cynthia C Early diagnosis and treatment of drug resistance in muc1-positive cancer
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
EP2214485B1 (en) 2007-09-25 2016-07-20 Minerva Biotechnologies Corp. Methods for treatment of cancer
DK2334703T3 (en) * 2008-09-17 2015-10-05 Innate Pharma Configurations and methods for detection of tlr3
EP3130607B1 (en) 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
WO2010042760A2 (en) 2008-10-08 2010-04-15 The Administrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
CN102272290B (zh) 2008-10-09 2018-08-14 米纳瓦生物技术公司 用于在细胞中诱导多能性的方法
WO2010056737A2 (en) 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
MX2011013385A (es) 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
EP3228629A1 (en) 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
WO2012154759A2 (en) 2011-05-09 2012-11-15 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
CN109456932A (zh) 2011-10-17 2019-03-12 米纳瓦生物技术公司 用于干细胞增殖和诱导的培养基
US20240247229A1 (en) 2011-10-17 2024-07-25 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
WO2013123084A1 (en) 2012-02-13 2013-08-22 Minerva Biotechnologies Corporation Method for detecting circulating fetal cells
AU2013222935B2 (en) * 2012-02-24 2016-03-10 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
AU2013289913A1 (en) 2012-07-13 2015-03-05 Minerva Biotechnologies Corporation Method for inducing cells to less mature state
WO2014018679A2 (en) 2012-07-24 2014-01-30 Minerva Biotechnologies Corporation Nme variant species expression and suppression
WO2014028668A2 (en) 2012-08-14 2014-02-20 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
CA2886161A1 (en) * 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
US20160326263A1 (en) 2013-02-20 2016-11-10 Minerva Biotechnologies Corporation NME Inhibitors and Methods of Using NME Inhibitors
CA2901893C (en) 2013-02-20 2022-08-30 Minerva Biotechnologies Corporation Nme inhibitors and methods of using nme inhibitors
AU2014306778B2 (en) 2013-08-12 2020-10-29 Minerva Biotechnologies Corporation Method for enhancing tumor growth
AU2015243948B2 (en) 2014-04-07 2020-10-15 Minerva Biotechnologies Corporation Anti-NME antibody
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
US20170106046A1 (en) 2015-03-03 2017-04-20 Minerva Biotechnologies Corporation Method for diagnosing and treating cancer using naive state stem cell specific genes
US20180235193A1 (en) 2015-07-01 2018-08-23 Minerva Biotechnologies Corporation Method of stem cell-based organ and tissue generation
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US11931347B2 (en) 2015-09-23 2024-03-19 Minerva Biotechnologies Corporation Method of screening for agents for differentiating stem cells
CN108409862B (zh) 2016-07-14 2021-07-13 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
WO2018054240A1 (en) 2016-09-20 2018-03-29 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pcsk9 antibodies
CA3039797A1 (en) 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
EP3600451B1 (en) 2017-03-29 2025-12-24 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
WO2019104306A1 (en) 2017-11-27 2019-05-31 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and direct use of cleavage enzyme
WO2019126357A1 (en) 2017-12-19 2019-06-27 Minerva Biotechnologies Corporation Agents for treating cancer and methods for identifying said agents
EP3759145A4 (en) 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
US20200405832A1 (en) 2018-03-09 2020-12-31 Minerva Biotechnologies Corporation Method for anti-muc1* car t cell stimulation
CN120484122A (zh) 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
EP4161970A4 (en) 2020-06-08 2024-07-10 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES
CA3183682A1 (en) * 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
US12104170B2 (en) 2020-06-26 2024-10-01 Minerva Biotechnologies Corporation Methods for deriving dopaminergic neurons from pluripotent stem cells
AU2021316042A1 (en) 2020-07-29 2023-03-30 Minerva Biotechnologies Corporation Anti-variable MUC1* antibodies and uses thereof
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
WO2023220560A1 (en) 2022-05-09 2023-11-16 Minerva Biotechnologies Corporation Chimeric antigen receptor and il-18 receptor compositions and methods of use therein
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases

Similar Documents

Publication Publication Date Title
JP7695193B2 (ja) 抗ｎｍｅ抗体および癌または癌転移の治療方法
US12479928B2 (en) Anti-cancer peptide
US12415868B1 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
JP2023532293A5 (cg-RX-API-DMAC7.html)
JP2023530039A5 (cg-RX-API-DMAC7.html)
US12049514B2 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
HK40101426A (zh) 抗nme抗体及治疗癌症或癌症转移的方法
AU2026202696A1 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
HK40094150A (zh) 抗nme抗体及治疗癌症或癌症转移的方法
HK40064429B (zh) 抗nme抗体及治疗癌症或癌症转移的方法
HK40064429A (en) Anti-nme antibody and method of treating cancer or cancer metastasis